Home › Compare › IPGGF vs ABBV
IPGGF yields 1654.26% · ABBV yields 3.12%● Live data
📍 IPGGF pulled ahead of the other in Year 1
Combined, IPGGF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IPGGF + ABBV for your $10,000?
Imperium Technology Group Limited, an investment holding company, manufactures and sells household furnishing products and accessories. The company operates through six segments: Game Publishing, Cloud Computing and Data Storage, Esports, Household Products, Property Investment, and Money Lending. It produces stainless steel home furnishing products for kitchens and bathrooms; and offers diversified financial products, including personal loans, home mortgages, equity financing and mortgage, and corporate finance. The company is also involved in cryptocurrency mining and rental of machines to customers to engage in cryptocurrency mining; and participating in esports competitions, streaming and marketing events, and merchandise sales. In addition, it invests in properties; and designs and develops mobile and computer games in Hong Kong, the People's Republic of China, East and South Asia, and internationally. The company was formerly known as Imperium Group Global Holdings Limited and changed its name to Imperium Technology Group Limited in July 2021. Imperium Technology Group Limited was founded in 1999 and is based in Kwun Tong, Hong Kong. Imperium Technology Group Limited is a subsidiary of Diamond State Holdings Limited.
Full IPGGF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.